While these patients express AFP well below established risk thresholds, current evidence suggests a subgroup of patients with aggressive HCC biology and higher disease progression risk in the absence of AFP elevation [2, 13] and suggests an urgent need for additional biomarkers. This evidence concerns the gene AFP and hepatocellular carcinoma.